Skip to content

R&D at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.65B+17.4%
Amgen logo
AmgenAMGN
$1.72B+15.7%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$29.15M+46.3%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$10.6M+0.3%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$73M+38.7%
Immunome logo
ImmunomeIMNM
$46.38M+25.8%

Segments

By segment

See full
Single Reportable$81.54M-15.6%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s R&D?
Alumis Inc. (ALMS) reported R&D of $81.54M in Q1 2026.
How has Alumis Inc.'s R&D changed year-over-year?
Alumis Inc.'s R&D decreased by 15.6% year-over-year, from $96.62M to $81.54M.
What is the long-term trend for Alumis Inc.'s R&D?
Over 2 years (2023 to 2025), Alumis Inc.'s R&D has grown at a 67.4% compound annual growth rate (CAGR), from $137.68M to $386M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.